BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 08, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Exalgo regulatory update

FDA approved an NDA for Exalgo hydromorphone to manage moderate to severe pain in opioid-tolerant patients. The approval triggers a $40 million milestone payment from U.S. commercialization partner Covidien to CombinatoRx, which merged with

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >